Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Inflammasome

Editor-in-Chief: Pelegrin, Pablo

Ed. by Lopez-Castejón, Gloria

1 Issue per year


Emerging Science

Open Access
Online
ISSN
2300-102X
See all formats and pricing
More options …

Inflammasome: a new villain in heart disease

Chiara Sonnino
  • Corresponding author
  • VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Stefano Toldo
  • VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA
  • Victoria Johnson Research Laboratory, Virginia Commonwealth University, Richmond, VA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Eleonora Mezzaroma
  • VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA
  • Victoria Johnson Research Laboratory, Virginia Commonwealth University, Richmond, VA, USA
  • Department of Pharmacotherapy and Outcome Studies, School of Pharmacy - Virginia Commonwealth University, Richmond, VA, USA
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Antonio Abbate
  • VCU Pauley Heart Center, Virginia Commonwealth University, Richmond, VA, USA
  • Victoria Johnson Research Laboratory, Virginia Commonwealth University, Richmond, VA, USA
  • James C. Roberts Esq. Professor of Cardiology, Virginia Commonwealth University, 1200 E. Broad Street, Box 980281, Richmond, VA, 23298, USA
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
Published Online: 2014-06-12 | DOI: https://doi.org/10.2478/infl-2014-0003

Abstract

Many cardiac diseases have an inflammatory component by which the initial injury is amplified by an overzealous inflammatory response leading to further tissue injury, and impairing the recovery of cardiac function. The formation of the inflammasome in the heart represents a newly identified amplifying step in the pathogenesis and pathophysiology of different cardiovascular conditions. Initial experimental animal studies and small pilot clinical studies suggest that targeting the inflammasome in its different components interrupts this amplification process and promotes more favorable healing. The inflammasome represents therefore a new villain in the fight against heart disease.

Keywords: Sterile Inflammation; Inflammasome; Heart Diseases

References

  • [1] Strowig T., Henao-Mejia J., Elinav E., Flavell R., Inflammasomes in health and disease, Nature, 2012, 481, 278-86 Google Scholar

  • [2] Stutz A., Golenbock D.T., Latz E., Inflammasomes: too big to miss, J. Clin. Invest., 2009, 119, 3502-11 Google Scholar

  • [3] Medzhitov R., Janeway C.A.Jr., Decoding the patterns of self and nonself by the innate immune system, Science, 2002, 296, 298-300 Google Scholar

  • [4] Marini M.G., Sonnino C., Previtero M., Biasucci L.M., Targeting inflammation: impact on atherothrombosis, J. Cardiovasc. Transl. Res., (2014, in press) Google Scholar

  • [5] Duewell P., Kono H., Rayner K.J., Sirois C.M., Vladimer G., et al., NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals, Nature, 2010, 464, 1357-61 Google Scholar

  • [6] Rajamäki K., Lappalainen J., Oörni K., Välimäki E., Matikainen S., et al., Cholesterol crystals activate the NLRP3 inflammasome in human macrophages: a novel link between cholesterol metabolism and inflammation, PLoS One, 2010, 5, e11765 Google Scholar

  • [7] Sheedy F.J., Grebe A., Rayner K.J., Kalantari P., Ramkhelawon B., Carpenter S.B., Becker C.E., Ediriweera H.N., Mullick A.E., Golenbock D.T., Stuart L.M., Latz E., Fitzgerald K.A., Moore K.J., CD36 coordinates NLRP3 inflammasome activation by facilitating the intracellular nucleation from soluble to particulate ligands in sterile inflammation, Nat Immunol, 2013, 14(8), 812–820 CrossrefGoogle Scholar

  • [8] Van Tassell B.W., Toldo S., Mezzaroma E., Abbate A., Targeting interleukin-1 in heart disease, Circulation, 2013, 128(17), 1910-23 Google Scholar

  • [9] Kirii H., Niwa T., Yamada Y., Wada H., Saito K., Iwakura Y., Asano M., Moriwaki H., Seishima M., Lack of interleukin-1beta decreases the severity of atherosclerosis in ApoE-deficient mice, Arterioscler Thromb Vasc Biol, 2003, 23(4), 656-60 CrossrefGoogle Scholar

  • [10] Chi H., Messas E., Levine R.A., Graves D.T., Amar S., Interleukin-1 receptor signaling mediates atherosclerosis associated with bacterial exposure and/or a high-fat diet in a murine apolipoprotein E heterozygote model: pharmacotherapeutic implications, Circulation, 2004, 110(12), 1678-85 Google Scholar

  • [11] Chamberlain J., Francis S., Brookes Z., Shaw G., Graham D., Alp N.J., Dower S., Crossman D.C., Interleukin-1 regulates multiple atherogenic mechanisms in response to fat feeding, PLoS One, 2009, 4(4):e5073 Google Scholar

  • [12] Bhaskar V., Yin J., Mirza A.M., Phan D., Vanegas S., Issafras H., Michelson K., Hunter J.J., Kantak S.S., Monoclonal antibodies targeting IL-1 beta reduce biomarkers of atherosclerosis in vitro and inhibit atherosclerotic plaque formation in Apolipoprotein E-deficient mice, Atherosclerosis, 2011, 216(2), 313-20 Google Scholar

  • [13] Alexander M.R., Moehle C.W., Johnson J.L., Yang Z., Lee J.K., Jackson C.L., Owens G.K., Genetic inactivation of IL-1 signaling enhances atherosclerotic plaque instability and reduces outward vessel remodeling in advanced atherosclerosis in mice, J Clin Invest, 2012, 122(1), 70-9 Google Scholar

  • [14] Menu P., Pellegrin M., Aubert J. F., Bouzourene K., Tardivel A., Mazzolai L., Tschopp J., Atherosclerosis in ApoE-deficient mice progresses independently of the NLRP3 inflammasome, Cell Death and Disease, 2011, 2, e137 Google Scholar

  • [15] Vandanmagsar B., Youm Y.H., Ravussin A., Galgani J.E., Stadler K., Mynatt R.L., et al., The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance, Nat Med., 2011, 17, 179–188 Google Scholar

  • [16] Wen H., Gris D., Lei Y., Jha S., Zhang L., Huang M.T., et al., Fatty acid-induced NLRP3-ASC inflammasome activation interferes with insulin signaling, Nat Immunol., 2011, 12, 408–415 CrossrefGoogle Scholar

  • [17] Stienstra R., Joosten L.A., Koenen T., van Tits B., van Diepen J.A., van den Berg S.A., et al., The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity, Cell Metab., 2010, 12, 593–605 CrossrefGoogle Scholar

  • [18] Yajima N., Takahashi M., Morimoto H., Shiba Y., Takahashi Y., Masumoto J., Ise H., Sagara J., Nakayama J., Taniguchi S., Ikeda U., Critical Role of Bone Marrow Apoptosis-Associated Speck-Like Protein, an inflammasome adaptor molecule, in neointimal formation after vascular injury in mice, Circulation, 2008, 117, 3079-3087 Google Scholar

  • [19] Chamberlain J., Evans D., King A., Dewberry R., Dower S., Crossman D., Francis S., Interleukin-1beta and signaling of interleukin-1 in vascular wall and circulating cells modulates the extent of neointima formation in mice, Am J Pathol, 2006, 168(4), 1396-403 Google Scholar

  • [20] Toldo S., Zhong H., Mezzaroma E., Van Tassell B.W., Kannan H., Zeng D., Belardinelli L., Voelkel N.F., Abbate A., GS-6201, a selective blocker of the A2B adenosine receptor, attenuates cardiac remodeling after acute myocardial infarction in the mouse, J Pharmacol Exp Ther, 2012, 343(3), 587-95 Google Scholar

  • [21] Mezzaroma E., Toldo S., Farkas D., Seropian I.M., Van Tassell B.W., Salloum F.N.,et al., The inflammasome promotes adverse cardiac remodeling following acute myocardial infarction in the mouse, Proc. Natl. Acad. Sci. U S A, 2011, 108, 19725-19730 Google Scholar

  • [22] Oka T., Hikoso S., Yamaguchi O., Taneike M., Takeda T., Tamai T., Oyabu J., Murakawa T., Nakayama H., Nishida K., Akira S., Yamamoto A., Komuro I., Otsu K., Mitochondrial DNA that escapes from autophagy causes inflammation and heart failure, Nature, 2012, 485(7397), 251-5 Google Scholar

  • [23] Takahashi M., NLRP3 Inflammasome as a Novel Player in Myocardial Infarction, Int. Heart. J., 2014, 55(2), 101-5 Google Scholar

  • [24] Stutz A., Horvath G.L., Monks B.G., Latz E. ASC Speck Formation as a Readout for Inflammasome Activation. Methods Mol Biol 2013;1040:91-101. CrossrefGoogle Scholar

  • [25] Kawaguchi M., Takahashi M., Hata T., Kashima Y., Usui F., Morimoto H., et al., Inflammasome Activation of Cardiac Fibroblasts Is Essential for Myocardial Ischemia/Reperfusion Injury, Circulation, 2011, 123, 594-604 Google Scholar

  • [26] Saxena A., Chen W., Su Y., Rai V., Uche O.U., Li N., Frangogiannis N.G., IL-1 induces proinflammatory leukocyte infiltration and regulates fibroblast phenotype in the infarcted myocardium, J. Immunol., 2013, 191(9), 4838-48 Google Scholar

  • [27] Sandanger Ø., Ranheim T., Vinge L.E., The NLRP3 inflammasome is up-regulated in cardiac fibroblasts and mediates myocardial ischaemia-reperfusion injury, Cardiovasc. Res., 2013, 99(1), 164-74 Google Scholar

  • [28] Marchetti C., Chojnacki J., Toldo S., Mezzaroma E., Tranchida N., Rose S.W., et al., A novel Pharmacologic inhibitor of the NLRP3 inflammasome limits myocardial injury following ischemia-reperfusion in the mouse, J. Cardiovasc. Pharmacol., (in press), DOI: Google Scholar

  • [29] Mezzaroma E., Toldo S., Abbate A., Role of NLRP3 (cryopyrin) in acute myocardial infarction, Cardiovasc. Res, 2013, 99(1), 225-6 Google Scholar

  • [30] Frantz S., Ducharme A., Sawyer D., Rohde L.E., Kobzik L., Fukazawa R., et al., Targeted deletion of caspase-1 reduces early mortality and left ventricular dilatation following myocardial infarction, J. Mol. Cell. Cardiol., 2003, 35(6), 685-94 CrossrefGoogle Scholar

  • [31] Merkle S., Frantz S., Schön M.P., Bauersachs J., Buitrago M., Frost R.J., et al., A role for caspase-1 in heart failure, Circ. Res., 2007, 100(5), 645-53 CrossrefGoogle Scholar

  • [32] Bujak M., Dobaczewski M., Chatila K., Mendoza LH., Li N., Reddy A., et al., Interleukin-1 receptor type I signaling critically regulates infarct healing and cardiac remodelling, Am. J. Pathol., 2008, 173, 57-67 Google Scholar

  • [33] Abbate A., Salloum F.N., Van Tassell B.W., Vecile E., Toldo S., Seropian I., et al., Alterations in the interleukin-1/interleukin-1 receptor antagonist balance modulate cardiac remodeling following myocardial infarction in the mouse, PLoS One, 2011, 6, e27923 Google Scholar

  • [34] Abbate A., Salloum F.N., Vecile E., Das A., Hoke N.N., Straino S.,et al., Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction, Circulation, 2008, 117, 2670-2683 Google Scholar

  • [35] Van Tassell B.W., Varma A., Salloum F.N., Das A., Seropian I.M., Toldo S., et al. Interleukin-1 trap attenuates cardiac remodeling after experimental acute myocardial infarction in mice, J. Cardiovasc. Pharmacol., 2010, 55(2), 117-22 Google Scholar

  • [36] Abbate A., Van Tassell B.W., Seropian I.M., Toldo S., Robati R., Varma A., Salloum F.N., Smithson L., Dinarello C.A.., Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse, Eur. J. Heart Fail., 2010, 12(4), 319-22 CrossrefGoogle Scholar

  • [37] Toldo S., Mezzaroma E., Van Tassell B.W., Farkas D., Marchetti C., Voelkel N.F., Abbate A., Interleukin-1β blockade improves cardiac remodelling after myocardial infarction without interrupting the inflammasome in the mouse, Exp. Physiol., 2013, 98(3), 734-45 Google Scholar

  • [38] Abbate A., Kontos M.C., Grizzard J.D., Biondi-Zoccai G.G., Van Tassell B.W., Robati R., et al., Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial [VCU-ART] Pilot study), Am. J. Cardiol., 2010, 105(10), 1371-1377.e1 Google Scholar

  • [39] Abbate A., Van Tassell B.W., Biondi-Zoccai G.G., Kontos M.C., Grizzard J.D., Spillman D.W., et al., Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction [from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study], Am. J. Cardiol., 2013, 111(10), 1394-400 Google Scholar

  • [40] Bracey N.A., Beck P.L., Muruve D.A., Hirota S.A., Guo J., Jabagi H., et al., The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β, Exp. Physiol., 2013, 98, 462–473 Google Scholar

  • [41] Toldo S., Kannan H., Bussani R., Anzini M., Sonnino C., Sinagra G., et al., Formation of the inflammasome in acute myocarditis, Int. J. Cardiol., 2014, 171 (3), e119-21 Google Scholar

  • [42] Sauter K.A., Wood L.J., Wong J., Iordanov M., Magun B.E., Doxorubicin and daunorubicin induce processing and release of interleukin-1β through activation of the NLRP3 inflammasome, Cancer Biol. Ther., 2011, 11(12), 1008-16 CrossrefGoogle Scholar

  • [43] Zhu J., Zhang J., Zhang L., Du R., Xiang D., Wu M., Interleukin-1 signaling mediates acute doxorubicin-induced cardiotoxicity, Biomed. Pharmacother., 2011, 65(7), 481-5 Google Scholar

  • [44] Zhu J., Zhang J., Xiang D., Zhang Z., Zhang L., Wu M., Recombinant human interleukin-1 receptor antagonist protects mice against acute doxorubicin-induced cardiotoxicity, Eur. J. Pharmacol., 2010, 643(2-3), 247-53Google Scholar

About the article

Received: 2014-02-24

Accepted: 2014-04-03

Published Online: 2014-06-12


Citation Information: Inflammasome, ISSN (Online) 2300-102X, DOI: https://doi.org/10.2478/infl-2014-0003.

Export Citation

©2014 Chiara Sonnino et al. This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License. BY-NC-ND 3.0

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Stefano Toldo, Eleonora Mezzaroma, Adolfo Gabriele Mauro, Fadi Salloum, Benjamin Wallace Van Tassell, and Antonio Abbate
Antioxidants & Redox Signaling, 2015, Volume 22, Number 13, Page 1146
[2]
Benjamin W. Van Tassell, Juan M. Valle Raleigh, and Antonio Abbate
Current Heart Failure Reports, 2015, Volume 12, Number 1, Page 33

Comments (0)

Please log in or register to comment.
Log in